Cipla has ended at Rs 309, up Rs 4.5 or 1.4%, on the BSE.
_____________________________________________
(Updated at 1105 am)
Cipla is quoting at Rs 312, higher by Rs 7 or 2.4%, on the BSE.
The stock opened at Rs 306 and has touched a high of Rs 313 and a low of Rs 305 thus far.
Cipla has recently launched generic versions of anti-flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza, which is spreading across the globe and in India. Cipla will brand oseltamivir as Antiflu and zanamivir as Virenza.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app